Glucagonlike peptide 1 analogs in diabetes care.
نویسندگان
چکیده
Bottom line Compared with placebo, semaglutide and liraglutide, but not lixisenatide, reduce cardiovascular disease (CVD) for about 1 in 50 patients with diabetes with existing CVD over 2 to 4 years, irrespective of specific hemoglobin A1c (HbA1c) targets. They reduce weight, but about 1 in 25 more patients than in the placebo group stopped treatment owing to gastrointestinal effects. Some uncertainty around neoplasm risk remains.
منابع مشابه
Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.
L iraglutide is a long-acting glucagonlike peptide (GLP)-1 analog, which exerts its glucose-lowering action through multiple mechanisms (1). One important feature of liraglutide is its ability to enhance -cell function. The effects on -cell function have been demonstrated using standardized -cell function tests based on intravenous glucose administration (2–4). However, these studies may not re...
متن کاملReceptor-mediated tumor targeting with radiolabeled peptides: there is more to it than somatostatin analogs.
In this issue of The Journal of Nuclear Medicine, Wild et al. report the binding and animal biodistribution data of [Lys(Ahx-DTPA-In)NH2]exendin-4 (Ahx is aminohexanoic acid; DTPA is diethylenetriaminepentaacetic acid), an analog of glucagonlike peptide-1 (GLP-1) (1). Their results raise high hopes of actually achieving selective and potent receptormediated targeting of tumors with a radiolabel...
متن کاملEfficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
CONTEXT Pharmacotherapies that augment the incretin pathway have recently become available, but their role in the management of type 2 diabetes is not well defined. OBJECTIVE To assess the efficacy and safety of incretin-based therapy in adults with type 2 diabetes based on randomized controlled trials published in peer-reviewed journals or as abstracts. DATA SOURCES We searched MEDLINE (19...
متن کاملThe incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease.
The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide (GIP) have been developed to treat type 2 diabetes and also act as growth factors. We have tested several long-acting incretin mimetics in the amyloid precursor protein (APP)(Swe)/presenilin 1 (PS1)(ΔE9) model of Alzheimer's disease (AD). We found that liraglutide, lixisenatide, and D-Ala2-GIP cross th...
متن کاملGlucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
IMPORTANCE Acute pancreatitis has significant morbidity and mortality. Previous studies have raised the possibility that glucagonlike peptide 1 (GLP-1)-based therapies, including a GLP-1 mimetic (exenatide) and a dipeptidyl peptidase 4 inhibitor (sitagliptin phosphate), may increase the risk of acute pancreatitis. OBJECTIVE To test whether GLP-1-based therapies such as exenatide and sitaglipt...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Canadian family physician Medecin de famille canadien
دوره 63 5 شماره
صفحات -
تاریخ انتشار 2017